Piper Sandler Boosts Karyopharm Therapeutics (NASDAQ:KPTI) Price Target to $5.00

Karyopharm Therapeutics (NASDAQ:KPTI - Get Free Report) had its price target increased by investment analysts at Piper Sandler from $4.00 to $5.00 in a note issued to investors on Wednesday, Benzinga reports. The brokerage currently has an "overweight" rating on the stock. Piper Sandler's price objective would suggest a potential upside of 461.80% from the stock's previous close.

KPTI has been the subject of several other reports. StockNews.com upgraded shares of Karyopharm Therapeutics from a "hold" rating to a "buy" rating in a research note on Thursday, August 8th. HC Wainwright restated a "buy" rating and set a $7.00 price objective on shares of Karyopharm Therapeutics in a research report on Friday, November 1st. Robert W. Baird cut their price objective on shares of Karyopharm Therapeutics from $8.00 to $5.00 and set an "outperform" rating for the company in a research report on Wednesday, August 7th. Finally, Royal Bank of Canada restated an "outperform" rating and set a $3.00 price objective on shares of Karyopharm Therapeutics in a research report on Wednesday, August 7th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $5.00.

Karyopharm Therapeutics Trading Up 5.2 %

Shares of Karyopharm Therapeutics stock traded up $0.04 during trading hours on Wednesday, reaching $0.89. 1,070,380 shares of the company's stock were exchanged, compared to its average volume of 1,269,440. The company has a 50 day moving average of $0.80 and a two-hundred day moving average of $0.91. Karyopharm Therapeutics has a fifty-two week low of $0.62 and a fifty-two week high of $1.95. The stock has a market cap of $110.97 million, a P/E ratio of -0.72 and a beta of 0.16.

Karyopharm Therapeutics (NASDAQ:KPTI - Get Free Report) last posted its quarterly earnings data on Tuesday, August 6th. The company reported ($0.20) EPS for the quarter, topping analysts' consensus estimates of ($0.29) by $0.09. The business had revenue of $42.79 million for the quarter, compared to analyst estimates of $36.07 million. As a group, analysts expect that Karyopharm Therapeutics will post -0.95 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. GSA Capital Partners LLP raised its position in Karyopharm Therapeutics by 80.6% during the third quarter. GSA Capital Partners LLP now owns 1,775,700 shares of the company's stock valued at $1,474,000 after purchasing an additional 792,283 shares in the last quarter. AQR Capital Management LLC raised its position in Karyopharm Therapeutics by 494.5% during the second quarter. AQR Capital Management LLC now owns 748,020 shares of the company's stock valued at $649,000 after purchasing an additional 622,194 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new position in Karyopharm Therapeutics during the second quarter valued at approximately $494,000. Ikarian Capital LLC raised its position in Karyopharm Therapeutics by 2.3% during the first quarter. Ikarian Capital LLC now owns 409,355 shares of the company's stock valued at $618,000 after purchasing an additional 9,355 shares in the last quarter. Finally, Exchange Traded Concepts LLC grew its stake in shares of Karyopharm Therapeutics by 34.9% in the third quarter. Exchange Traded Concepts LLC now owns 218,791 shares of the company's stock worth $182,000 after purchasing an additional 56,613 shares during the last quarter. 66.44% of the stock is currently owned by institutional investors and hedge funds.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).